CELL THERAPY

细胞疗法

• 批准号: 7318396
• 负责人: James William Young
• 金额: $ 23.99万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-01 至 2012-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7318396
• 关键词: Address; Allogenic; Allografting; Ambulatory Care Facilities; Antigens; Area; B-Lymphocytes; Biological Assay; Biology; Cell Line; Cell Therapy; Cell physiology; Clinical; Clinical Trials; Cytomegalovirus; Dendritic Cells; Disease; Flow Cytometry; Generations; Hematopoietic Stem Cell Transplantation; Human; Immunotherapy; Inpatients; Laboratories; Lymphocyte; Lymphocyte Activation; Lymphoid; Malignant Neoplasms; Medical; Monitor; Myelogenous; Natural Killer Cells; Numbers; Opportunistic Infections; Outcome; Patient Care; Patients; Production; Public Health; Recurrence; Research; Resources; Siblings; Specimen; Structure of thyroid parafollicular cell; T-Lymphocyte; Transplantation; cost; improved; older patient; programs; reconstitution; repository; research and development; translational clinical trial

Core C: Cell Therapy. This is a new core that will take advantage of new physical space resources to consolidate efforts relating to cell therapies developed and applied in this program. This core will therefore provide four specific functions: (1) specimen procurement, prioritization, and distribution for research, in coordination with the Clinical Cytotherapy/Transplant Laboratory, inpatient units, and outpatient clinics, and including a centralized storage repository (all Projects 1-6); (2) graft characterization by flow cytometry, clonogenic assays, and lymphocyte functional assays to develop predictors of graft outcome (Project 6); (3) production and release of NK cells and antigen (CMV and WT-1)-specific T cells for adoptive immunptherapy, including the generation of human dendritic cells and EBV-transformed B cell lines for lymphocyte stimulation and expansion ex vivo (Projects 1, 4, and 6); and (4) coordinated QA/QC oversight of these activities (Project 6). The actual cell processing for hematopoietic stem cell transplantation will remain with the Clinical Cytotherapy Laboratory. Additionally, the activities conducted by the Clinical Cytotherapy Laboratory are largely billable as clinical patient care and do not require support from this core. This core will also interact with Core B by providing the upfront graft characterization that will help interpret posttransplant monitoring of myeloid (including dendritic cell) and lymphoid reconstitution pertinent to graft outcome. The integration of these previously separate efforts will provide greater efficiency of effort and costs, will enhance patient care by improved characterization of allograft biology, and will provide NK and Ag-specific T cell therapies to address major early complications of disease recurrence and opportunistic infections. Lay summary and public health relevance: Fewer complications and the availability of alternative donors to matched siblings have made allogeneic hematopoietic stem cell transplantation available to larger numbers of patients. These include older patients and those with coexisting medical problems. Laboratory support provided by this Core will sustain research and development in this area as well as translational applications in the proposed clinical trials. These activities will help improve the overall outcomes of patients undergoing allogeneic transplant each year for an increasing variety of malignancies.

核心C：细胞疗法。这是一个新的核心，将利用新的物理空间资源来 巩固与该计划中开发和应用的细胞疗法有关的努力。因此，这个核心将 提供四个具体职能：(1)样本采购、优先排序和研究分发 与临床细胞治疗/移植实验室、住院单位和门诊诊所协调，以及 包括集中存储储存库(所有项目1-6)；(2)通过流式细胞仪进行移植物表征， 克隆形成试验和淋巴细胞功能分析以开发移植结果的预测因子(项目6)；(3) 过继免疫中NK细胞和抗原(CMV和WT-1)特异性T细胞的产生和释放 免疫治疗，包括人树突状细胞和EBV转化的B细胞系的产生 淋巴细胞刺激和体外扩增(项目1、4和6)；和(4)协调QA/QC监督 这些活动(项目6)。造血干细胞移植的实际细胞处理将继续 在临床细胞治疗实验室工作。此外，临床细胞治疗中心开展的活动 实验室在很大程度上是作为临床病人护理收费的，不需要这一核心的支持。这个核心 还将通过提供有助于解释移植后情况的预先移植物特征与核心B进行交互 与移植物相关的髓系(包括树突状细胞)和淋巴系重建的监测 结果。整合这些以前分开的努力将提供更高的工作效率和 成本，将通过改善同种异体移植生物学的特征来加强患者护理，并将提供NK和 针对疾病复发和机会性的主要早期并发症的抗原特异性T细胞疗法 感染。 LE摘要和公共卫生相关性：并发症较少和可获得替代捐赠者 匹配的兄弟姐妹使异基因造血干细胞移植适用于更大的 病人数量。这些患者包括老年患者和那些同时存在医疗问题的患者。实验室 本核心提供的支持将支持这一领域的研究和开发以及翻译 在拟议的临床试验中的应用。这些活动将有助于改善患者的整体预后。 每年为越来越多的恶性肿瘤进行同种异体移植。